載入中
HKSEHealthcareMedical - Care Facilities
最新資料
HK$9.61
+HK$0.12 · +1.26%
Hygeia Healthcare Holdings Co., Limited (6078.HK) is a prominent oncology healthcare provider primarily operating across the People's Republic of China. The company owns and manages a network of private, for-profit hospitals specializing in comprehensive cancer care. These facilities offer a broad spectrum of services, including diagnostic procedures such as tumor screening and genetic analysis, advanced therapeutic interventions like radiotherapy, surgery, chemotherapy, immunotherapy, and targeted treatments, alongside crucial supportive care including oncology rehabilitation, nutritional guidance, and hospice services. Beyond direct patient care, Hygeia also provides consulting expertise for radiotherapy centers and licenses its specialized SRT (Stereotactic Radiotherapy) equipment, offering ongoing maintenance and technical support for these systems. The company's operations extend to providing hospital and corporate management services, as well as supply chain solutions. By the end of 2021, Hygeia Healthcare had established a significant presence, operating or managing 12 oncology-focused hospitals spread across 9 cities in 7 provinces throughout mainland China. Established in 2009, the company maintains its headquarters in Shanghai, PRC.
最新資料
HK$9.61
+HK$0.12 · +1.26%
盤中時間採用HKT。市場資料可能有所延遲。
Hygeia Healthcare Holdings Co., Limited (6078.HK) is a prominent oncology healthcare provider primarily operating across the People's Republic of China. The company owns and manages a network of private, for-profit hospitals specializing in comprehensive cancer care. These facilities offer a broad spectrum of services, including diagnostic procedures such as tumor screening and genetic analysis, advanced therapeutic interventions like radiotherapy, surgery, chemotherapy, immunotherapy, and targeted treatments, alongside crucial supportive care including oncology rehabilitation, nutritional guidance, and hospice services. Beyond direct patient care, Hygeia also provides consulting expertise for radiotherapy centers and licenses its specialized SRT (Stereotactic Radiotherapy) equipment, offering ongoing maintenance and technical support for these systems. The company's operations extend to providing hospital and corporate management services, as well as supply chain solutions. By the end of 2021, Hygeia Healthcare had established a significant presence, operating or managing 12 oncology-focused hospitals spread across 9 cities in 7 provinces throughout mainland China. Established in 2009, the company maintains its headquarters in Shanghai, PRC.
日內區間
目前HK$9.61
52週區間
目前HK$9.61
盤中時間採用HKT。市場資料可能有所延遲。
Hygeia Healthcare Holdings Co., Limited (6078.HK) is a prominent oncology healthcare provider primarily operating across the People's Republic of China. The company owns and manages a network of private, for-profit hospitals specializing in comprehensive cancer care. These facilities offer a broad spectrum of services, including diagnostic procedures such as tumor screening and genetic analysis, advanced therapeutic interventions like radiotherapy, surgery, chemotherapy, immunotherapy, and targeted treatments, alongside crucial supportive care including oncology rehabilitation, nutritional guidance, and hospice services. Beyond direct patient care, Hygeia also provides consulting expertise for radiotherapy centers and licenses its specialized SRT (Stereotactic Radiotherapy) equipment, offering ongoing maintenance and technical support for these systems. The company's operations extend to providing hospital and corporate management services, as well as supply chain solutions. By the end of 2021, Hygeia Healthcare had established a significant presence, operating or managing 12 oncology-focused hospitals spread across 9 cities in 7 provinces throughout mainland China. Established in 2009, the company maintains its headquarters in Shanghai, PRC.
日內區間
目前HK$9.61
52週區間
目前HK$9.61
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CNY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 40.09億 CNY | 44.46億 CNY | 40.77億 CNY | 31.96億 CNY | 23.15億 CNY |
| 銷貨成本 | 29.85億 CNY | 31.17億 CNY | 28.1億 CNY | 21.79億 CNY | 15.71億 CNY |
| 毛利 | 10.23億 CNY | 13.29億 CNY | 12.67億 CNY | 10.17億 CNY | 7.45億 CNY |
| 研究與開發 | 1004.6萬 CNY | 1323.7萬 CNY | — | — | — |
| 銷售、一般及管理費用 | 4.7億 CNY | 4.91億 CNY | 4.13億 CNY | 2.93億 CNY | 2.25億 CNY |
| 營業費用 | 6.3億 CNY | 5.08億 CNY | 3.78億 CNY | 3.5億 CNY | 1.51億 CNY |
| 利息收入 | 325.5萬 CNY | 151.4萬 CNY | 1015.3萬 CNY | 1731.8萬 CNY | 215.5萬 CNY |
| 利息支出 | 6914.7萬 CNY | 7184.2萬 CNY | 4317萬 CNY | 3488.1萬 CNY | 2308.5萬 CNY |
| 折舊和攤銷 | 3.04億 CNY | 2.95億 CNY | 2.11億 CNY | 1.53億 CNY | 1.14億 CNY |
| 營業利益 | 3.93億 CNY | 8.21億 CNY | 8.89億 CNY | 6.67億 CNY | 5.94億 CNY |
| 淨利 | 1.65億 CNY | 5.98億 CNY | 6.83億 CNY | 4.77億 CNY | 4.41億 CNY |
公司資料更新於 2026年10月10日。
近期已公布業績
近期已公布業績
年度分割調整後的每股現金分配。
HK$0.1636
2023年（完整年度）+13.6% 自從 2021
HK$0.1441
2,021
HK$0.1636
2,023
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2023年6月30日 | HK$0.1636Irregular | 2023年7月3日 | 2023年7月27日 |
股息 | 2021年6月30日 | HK$0.1441Irregular | 2021年7月5日 | 2021年7月26日 |
除息 2023年6月30日
HK$0.1636
Irregular
2023年7月3日登記 · 支付日 2023年7月27日
除息 2021年6月30日
HK$0.1441
Irregular
2021年7月5日登記 · 支付日 2021年7月26日
報告持有此股票曝險的交易所交易基金。
Vanguard Total International Stock ETFVXUS644.39萬0.00%6657億 USD0.05%US$84.82+0.86%
iShares Core MSCI Emerging Markets ETFIEMG601.1萬0.00%1589.63億 USD0.09%US$81.40+1.12%
Vanguard FTSE Emerging Markets ETFVWO594.69萬0.00%1685億 USD0.06%US$59.76+1.12%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS225.78萬0.01%145億 USD0.06%US$155.12+0.98%
iShares Core MSCI Total International Stock ETFIXUS138.43萬0.00%582.06億 USD0.07%US$94.99+0.90%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM83.58萬0.01%96.67億 USD0.39%US$40.01+1.07%
State Street SPDR Portfolio Emerging Markets ETFSPEM63.31萬0.00%175.23億 USD0.07%US$52.21+1.32%
Avantis Emerging Markets Equity ETFAVEM50.71萬—281.73億 USD0.33%US$94.11+0.93%Vanguard Total International Stock ETFVXUSiShares Core MSCI Emerging Markets ETFIEMGVanguard FTSE Emerging Markets ETFVWOVanguard FTSE All-World ex-US Small-Cap ETFVSSiShares Core MSCI Total International Stock ETFIXUSDimensional - Emerging Markets Core Equity 2 ETFDFEMState Street SPDR Portfolio Emerging Markets ETFSPEMAvantis Emerging Markets Equity ETFAVEMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。